EcoDrugPlus

Metabotropic Glutamate Receptor 2-Like

Ensembl ID : ENSPNYG00000014736
Gene Symbol: LOC102210090
3 Cross references
206 Possible Orthologues:

Metabotropic Glutamate Receptor 5-Like

Ensembl ID : ENSPNYG00000023179
Gene Symbol: LOC102195551
3 Cross references
211 Possible Orthologues:

Methionine Aminopeptidase 2-Like

Ensembl ID : ENSPNYG00000021636
Gene Symbol: LOC102214276
4 Cross references
220 Possible Orthologues:

Microtubule-Associated Protein Tau-Like

Ensembl ID : ENSPNYG00000020674
Gene Symbol: LOC102192269
2 Cross references
205 Possible Orthologues:

Mitogen-Activated Protein Kinase 1

Ensembl ID : ENSPNYG00000005403
Gene Symbol: MAPK1
3 Cross references
209 Possible Orthologues:

Mitogen-Activated Protein Kinase 1-Like

Ensembl ID : ENSPNYG00000017030
Gene Symbol: LOC102209716
3 Cross references
197 Possible Orthologues:

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSPNYG00000006997
Gene Symbol: MAPK10
3 Cross references
88 Possible Orthologues:

Mitogen-Activated Protein Kinase 11-Like

Ensembl ID : ENSPNYG00000011822
Gene Symbol: LOC102211115
3 Cross references
199 Possible Orthologues:

Mitogen-Activated Protein Kinase 14

Ensembl ID : ENSPNYG00000008186
Gene Symbol: MAPK14
4 Cross references
224 Possible Orthologues:

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSPNYG00000003014
Gene Symbol: MAPK8
3 Cross references
224 Possible Orthologues:

Mitogen-Activated Protein Kinase 8-Like

Ensembl ID : ENSPNYG00000009838
Gene Symbol: LOC102205276
4 Cross references
221 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSPNYG00000000311
Gene Symbol: MAPK9
3 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).